We are looking for individuals living in Adelaide that suffer from recurrent UTIs to participate in a study investigating the benefits of cranberry supplementation.
The consumption of cranberries (Vaccinium macrocarpon) has long been investigated as a potential therapeutic intervention for the prevention of recurrent UTI. While the mechanism remains unclear, cranberries contain a number of bioactive components that are suggested to contribute to good urinary tract health. However, despite a large amount of research, little consensus exists. This inconsistency may be due to the type of cranberry product being tested.
In this study, we will be testing a high strength cranberry supplement obtained using the whole fruit. Most other Cranberry products use components of the cranberry. By using the whole fruit, this may ensure no potentially bioactive component of cranberry is lost through manufacturing.
About this study
The aim of this research study is to investigate the effect of daily consumption of a high strength cranberry supplement for the prevention of recurrent UTI in at risk women. Participants will be required to attend the CSIRO Nutrition and Health Research Clinic at SAHMRI, North Terrace Adelaide to have blood and urine samples collected.
On completion of the study, participants will receive a Coles/Myer gift card valued at $500 to acknowledge their valuable contribution to scientific research.
You will need to meet the following criteria to participate in this study:
- female, aged 18-65
- had 3 or more UTIs in the past year or at least 2 UTIs in the past 6 months
- willing to consume a soft gel capsule supplement daily for 6 months
- attend at least 3 appointments over a 6 month period at the CSIRO clinic located at SAHMRI North Terrace, Adelaide
Participate in this study
If you have any queries about the Cranberry UTI study or would like further information please call +61 8 8305 0615 or email CRUstudies@csiro.au.
If you would like to participate in this study please complete the online form.
This study has been approved by the CSIRO Health and Medical Research Human Research Ethics Committee.